We are live on !
Find out more
Pfizer Portfolio holdings
AUM
$170M
Turnover
5.56%
1-Year Est. Return
191.09%
This Fund
S&P 500
This Quarter Est. Return
+36.31%
1 Year Est. Return
+191.09%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$236M
AUM Growth
-$201M
(-46%)
Cap. Flow
-$225M
Cap. Flow % of AUM
Cap. Flow %
-95.03%
Top 10 Holdings %
Top 10 Hldgs %
95.36%
Holding
21
New
–
Increased
–
Reduced
–
Closed
3
Avg Time Held
1
year
Top 10 Avg Time Held
0.6
years
Top 20 Avg Time Held
0.9
years
Top Buys
No buys this quarter
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
BioNTech
BNTX
|
+$164M |
| 2 |
Tourmaline Bio
TRML
|
+$60.8M |
| 3 |
ESSA Pharma
EPIX
|
+$320K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
1
Oric Pharmaceuticals
ORIC
$1.41B
| $44M | 18.6% |
5,376,344
| – | – |
2024 Q4
4 quarters
|
|
2
Arvinas
ARVN
$505M
| $41M | 17.34% |
3,457,815
| – | – |
2024 Q4
4 quarters
|
|
3
Celcuity
CELC
$3.21B
| $34.8M | 14.74% |
349,406
| – | – |
2024 Q4
4 quarters
|
|
4
Wave Life Sciences
WVE
$660M
| $31.9M | 13.48% |
1,875,000
| – | – |
2024 Q4
4 quarters
|
|
5
Allogene Therapeutics
ALLO
$432M
| $30.2M | 12.76% |
22,032,040
| – | – |
2024 Q4
4 quarters
|
|
6
Zura Bio
ZURA
$338M
| $15.6M | 6.58% |
2,970,022
| – | – |
2024 Q4
4 quarters
|
|
7
Pyxis Oncology
PYXS
$143M
| $8.09M | 3.42% |
7,032,770
| – | – |
2024 Q4
4 quarters
|
|
8
Caribou Biosciences
CRBU
$60M
| $7.46M | 3.15% |
4,690,431
| – | – |
2024 Q4
4 quarters
|
|
9
Cardiff Oncology
CRDF
$72.2M
| $6.78M | 2.87% |
2,411,575
| – | – |
2024 Q4
4 quarters
|
|
10
Biohaven
BHVN
$2.22B
| $5.71M | 2.41% |
505,645
| – | – |
2024 Q4
4 quarters
|
|
11
Spero Therapeutics
SPRO
$65.8M
| $5.5M | 2.33% |
2,362,348
| – | – |
2024 Q4
4 quarters
|
|
12
NextCure
NXTC
$21.6M
| $2.24M | 0.95% |
157,646
| – | – |
2024 Q4
4 quarters
|
|
13
Zentalis Pharmaceuticals
ZNTL
$228M
| $1.29M | 0.54% |
953,834
| – | – |
2024 Q4
4 quarters
|
|
14
Q32 Bio
QTTB
$262M
| $922K | 0.39% |
277,777
| – | – |
2024 Q4
4 quarters
|
|
15
AN2 Therapeutics
ANTX
$137M
| $815K | 0.34% |
715,295
| – | – |
2024 Q4
4 quarters
|
|
16
Bolt Biotherapeutics
BOLT
$8.07M
| $171K | 0.07% |
31,305
| – | – |
2024 Q4
4 quarters
|
|
17
Ginkgo Bioworks
DNA
$654M
| $24.3K | 0.01% |
2,928
| – | – |
2024 Q4
4 quarters
|
|
18
Senseonics Holdings Inc
SENS
$391M
| $12K | 0.01% |
2,171
| – | – |
2024 Q4
4 quarters
|
|
|
19
BioNTech
BNTX
$22.5B
| – | – |
-1,658,361
| Closed | -$164M | – |
|
|
20
DELISTED
ESSA Pharma
EPIX
| – | – |
-1,675,000
| Closed | -$320K | – |
|
|
21
DELISTED
Tourmaline Bio
TRML
| – | – |
-1,272,214
| Closed | -$60.8M | – |
|
Similar funds
Pfizer's Q4 2025 Portfolio in Review
As of Q4 2025, Pfizer held 21 positions worth $236M, down 46% from $437M the previous quarter. Its ten largest holdings account for 95% of the portfolio.
Pfizer withdrew a net $225M in Q4 2025, closing 3 positions. Its most notable exit was BioNTech, an estimated $164M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.
- Pfizer fully exited BioNTech in Q4 2025, selling an estimated $164M.
- Pfizer's ten largest holdings make up 95% of its $236M portfolio in Q4 2025.
- Pfizer opened 0 new positions and closed 3 in Q4 2025.
- Pfizer's portfolio value fell 46% quarter-over-quarter to $236M.
Based on Pfizer's 13F filing for Q4 2025, filed 12 Feb 2026.